Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.
Quote | Glaukos Corporation (NYSE:GKOS)
Last: | $119.82 |
---|---|
Change Percent: | -1.28% |
Open: | $119.16 |
Close: | $119.82 |
High: | $120.15 |
Low: | $117.45 |
Volume: | 613,359 |
Last Trade Date Time: | 07/26/2024 03:00:00 am |
News | Glaukos Corporation (NYSE:GKOS)
2024-07-10 12:52:04 ET More on Glaukos, Intuitive Surgical, etc. Glaukos Stock: Still Unproven Whether A New Bull Market Has Begun Tandem Diabetes Care: Recent Rally Fully Deserved, Likely More Upside Here Intuitive Surgical: Hope For A Resurgence In Operational Leve...
Conference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2024 fin...
Message Board Posts | Glaukos Corporation (NYSE:GKOS)
Subject | By | Source | When |
---|---|---|---|
This could run hard with volume | masterofdisaster | investorshub | 07/30/2021 2:23:47 PM |
I put a bid in on the Aug. | masterofdisaster | investorshub | 07/15/2021 11:47:00 AM |
Priced a little high for me. I was | KOmani | investorshub | 07/15/2021 11:45:10 AM |
I was thinking about buying some $60 call options | masterofdisaster | investorshub | 07/14/2021 9:07:03 PM |
Anyone else trading this hoping it can test $60? | KOmani | investorshub | 07/14/2021 2:51:02 PM |
News, Short Squeeze, Breakout and More Instantly...
Conference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2024 fin...
Shares of Glaukos Corporation (NYSE: GKOS) traded at a new 52-week high today and are currently trading at $120.11. So far today, approximately 152.81k shares have been exchanged, as compared to an average 30-day volume of 541.53k shares. Glaukos Corporation, an ophthalmic medical technology ...
2024-07-01 22:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...